title: [Standardization of invasive neuromodulatory procedures].
abstract: The Working Group on Neuromodulation of the German Association for the Study of Pain, composed of representatives from various scientific specialty societies, met on December 9, 2000, March 24, 2001, October 5, 2001, and December 8, 2001. As a result of these discussions grounded in current knowledge, the following guidelines were formulated for the standardization of invasive techniques of neuromodulation intended to serve as a systematic aid in decision-making and to provide recommendations for practice-oriented methods. The guidelines were based on both the clinical and practical experience of the group participants (see information box on the next page) as well as on the current scientific literature and guidance from the consensus report of the European Federation of IASP Chapters (EFIC) [23]. The guidelines serve the purpose of orientation and have no effect on either assumption of liability or discharge from liability. The guidelines were conceived for use by physicians in private practice,doctors in hospitals,and nonmedical personnel concerned with the care of chronic pain patients. The Working Group consists of unsalaried volunteers. The participants received no honorarium and were only reimbursed for normal travel expenses in accordance with customary directives. The guidelines will be revised should new scientific results become available, at the latest in 2 years. The plan exists to further develop the guidelines to stages II and III (AWMF). The Steering Committee of the DGSS appraised the guidelines and authorized the guidelines before publication.
authors.affiliation: Klinik für Anästhesie und spezielle Schmerztherapie, Klinikum Krefeld. harke@klinikum-krefeld.de
authors.forename: H
authors.initials: H
authors.lastname: Harke
authors.forename: E
authors.initials: E
authors.lastname: Rosenow
authors.forename: V
authors.initials: V
authors.lastname: Tronnier
authors.forename: C
authors.initials: C
authors.lastname: Fromme
authors.forename: G
authors.initials: G
authors.lastname: Deynet
authors.forename: P
authors.initials: P
authors.lastname: Gretenkort
authors.forename: D
authors.initials: D
authors.lastname: Buschmann
authors.forename: P
authors.initials: P
authors.lastname: Rohr
authors.forename: H U
authors.initials: HU
authors.lastname: Ladleif
authors.forename: E
authors.initials: E
authors.lastname: von Glinski
authors.forename: G
authors.initials: G
authors.lastname: Schütze
authors.forename: R
authors.initials: R
authors.lastname: Schultze
authors.forename: H L
authors.initials: HL
authors.lastname: Keller
authors.forename: B
authors.initials: B
authors.lastname: Kniesel
authors.forename: R
authors.initials: R
authors.lastname: Pfeifer
authors.forename: E
authors.initials: E
authors.lastname: Lux
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D005060:Europe; D006801:Humans; D007278:Injections, Spinal; D018377:Neurotransmitter Agents / Q000502:physiology*; D010148:Intractable Pain / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology; D017410:Practice Guidelines as Topic / Q000592:standards*; D011785:Quality Assurance, Health Care
chemical_list: D000700:Analgesics; D018377:Neurotransmitter Agents